| 6.83 0.24 (3.64%) | 12-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.91 | 1-year : | 11.82 |
| Resists | First : | 8.48 | Second : | 10.11 |
| Pivot price | 6.63  |
|||
| Supports | First : | 5.84 | Second : | 4.86 |
| MAs | MA(5) : | 6.59 |
MA(20) : | 7.1 |
| MA(100) : | 14.59 |
MA(250) : | 0 | |
| MACD | MACD : | -1.7 |
Signal : | -2 |
| %K %D | K(14,3) : | 26.4 |
D(3) : | 21.5 |
| RSI | RSI(14): 34.9 |
|||
| 52-week | High : | 24.17 | Low : | 5.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ARCT ] has closed below upper band by 39.2%. Bollinger Bands are 73.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.86 - 6.89 | 6.89 - 6.92 |
| Low: | 6.39 - 6.43 | 6.43 - 6.46 |
| Close: | 6.77 - 6.83 | 6.83 - 6.89 |
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Mon, 01 Dec 2025
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know - Your Wyoming Link
Mon, 24 Nov 2025
Arcturus Therapeutics to Attend Upcoming Investor Conference - Business Wire
Thu, 13 Nov 2025
Citigroup Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation - Nasdaq
Tue, 11 Nov 2025
Piper Sandler Maintains Arcturus Therapeutics Holdings (ARCT) Overweight Recommendation - Nasdaq
Mon, 10 Nov 2025
Arcturus Therapeutics Holdings Inc earnings missed by $6.02, revenue fell short of estimates - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 85.5 (%) |
| Shares Short | 9,210 (K) |
| Shares Short P.Month | 5,310 (K) |
| EPS | -2.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.23 |
| Profit Margin | -68.4 % |
| Operating Margin | -96.3 % |
| Return on Assets (ttm) | -15 % |
| Return on Equity (ttm) | -27.5 % |
| Qtrly Rev. Growth | -58.8 % |
| Gross Profit (p.s.) | -3.33 |
| Sales Per Share | 3.43 |
| EBITDA (p.s.) | -2.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -58 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -2.78 |
| PEG Ratio | 0 |
| Price to Book value | 0.82 |
| Price to Sales | 1.98 |
| Price to Cash Flow | -3.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|